Holen Sie sich die Stockscreener-App
7.33
0.95%
-0.07
Vorhandelsmarkt:
7.45
0.12
+1.64%
Schlusskurs vom Vortag:
$7.40
Offen:
$7.4
24-Stunden-Volumen:
327.69K
Relative Volume:
2.97
Marktkapitalisierung:
$777.23M
Einnahmen:
$117.05M
Nettoeinkommen (Verlust:
$-3.71M
KGV:
-94.09
EPS:
-0.0779
Netto-Cashflow:
$1.67M
1W Leistung:
+2.09%
1M Leistung:
+13.82%
6M Leistung:
+5.62%
1J Leistung:
-0.54%
1-Tages-Spanne:
$6.81
$7.44
1-Wochen-Bereich:
$6.81
$7.61
52-Wochen-Spanne:
$5.44
$9.42
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Firmenname
Gyre Therapeutics Inc
Sektor
Branche
Telefon
(858) 284-0115
Adresse
12730 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
7.33 | 777.23M | 117.05M | -3.71M | 1.67M | -0.0779 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | Jefferies | Buy |
| 2025-08-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-11 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-04-29 | Fortgesetzt | Stephens | Overweight |
| 2021-02-10 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-21 | Eingeleitet | Raymond James | Outperform |
| 2019-01-04 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-12 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-12-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-06-06 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-06-30 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Gyre Therapeutics Inc Aktie (GYRE) Neueste Nachrichten
Gyre Therapeutics stock holds steady as investors await next clinical and earnings milestones - AD HOC NEWS
Gyre Therapeutics, Inc.Common Stock (Nasdaq:GYRE) Detailed Stock Data - The Chronicle-Journal
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a 159.98% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Gyre Therapeutics Q2 2026 Earnings: Wider-Than-Expected Loss, Yet Shares Rise 6.57%Earnings Growth Forecast - careplusvn.com
GYRE: Integrated China-U.S. model drives innovation, revenue, and a robust clinical pipeline - TradingView
GYRE: Integrated China-U.S. model drives pipeline growth, with key catalysts in fibrosis and cancer pain - TradingView
GYRE Q2 2026 Earnings: Wider-than-Expected Loss But Shares Advance 4.52%Full Year Guidance - careplusvn.com
Gyre Therapeutics to Participate in Upcoming September Investor Conferences - The Manila Times
Two live online healthcare talks will feature Gyre Therapeutics this month - Stock Titan
Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy - The Globe and Mail
Gyre updates corporate presentation, outlines China-driven R&D and F351 regulatory progress - TradingView
Gyre Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
GYRE Q2 2026 Earnings: Wider Net Loss of $0.12 Per Share Highlights Clinical-Stage SpendingMargin Compression Risk - dars.gov.et
Gyre Therapeutics unveils capital-efficient global development strategy - The Globe and Mail
Gyre Therapeutics posts updated corporate presentation detailing pipeline progress and China-commercial revenue drivers - TradingView
Gyre (GYRE) Results Review: The EPS Result Is Below Expectation in the Latest Session; After Results: Shares Move 1.82% Down for the Current SessionBalance Sheet Strength - vinanet.vn
Gyre (GYRE): Slides 2.10% to $7.00 in Latest Trading; Trading Range: Price Remains Between $6.65 Support and $7.35 ResistanceBackspread Trade - vinanet.vn
Gyre Therapeutics (NASDAQ:GYRE) Lowered to "Strong Sell" Rating by Zacks Research - MarketBeat
Analysts Set Expectations for GYRE Q3 Earnings - MarketBeat
GYRE | Gyre Therapeutics, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Claire Weston Net Worth (2026) - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN) - The Globe and Mail
Noble Financial Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Gyre Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Gyre Therapeutics Inc (GYRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gyre Therapeutics earnings missed by $0.06, revenue topped estimates - Investing.com Nigeria
GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Lights a Fire Under SharesEarnings Deceleration Risk - careplusvn.com
Gyre Therapeutics (NASDAQ:GYRE) Issues Earnings Results - MarketBeat
Form 8K Gyre Therapeutics Inc For: 7 August By Investing.com - Investing.com Nigeria
GYRE: Net loss widened to $32.8 million on $53.5 million revenue, with strong liquidity maintained - TradingView
Gyre Therapeutics (NASDAQ: GYRE) swings to 32,849 H1 2026 net loss - Stock Titan
Gyre Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
H.C. Wainwright Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Gyre Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Gyre Therapeutics Q2 EPS misses estimate despite sales beat - scanx.trade
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Gyre Therapeutics Sees 2026 Rev $100.5M-$111.0M >GYRE - Moomoo
Gyre Therapeutics Reports Second Quarter 2026 - Moomoo
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
GYRE Q2 Revenue Falls To $29.1 Million As Net Loss Widens - Quiver Quantitative
GYRE: Q2 2026 revenue reached $29.1M, net loss widened, and Cullgen acquisition expanded the pipeline - TradingView
Gyre Therapeutics reports Q2 2026 revenue $29.1M, GAAP EPS $(0.12); full-year revenue guidance affirmed - TradingView
Gyre Therapeutics, Inc. Affirms Earnings Guidance for the Full Year of 2026 - marketscreener.com
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: A 191% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
About $300M Cullgen deal adds cancer candidates to Gyre's pipeline - Stock Titan
L9S.DU interactive stock chart | Gyre Therapeutics Inc. R stock - Yahoo Finance Australia
Gyre Therapeutics, Inc. (GYRE) grants director options on 40,000 shares - Stock Titan
Gyre Therapeutics (GYRE) director discloses no stock ownership - Stock Titan
Gyre Therapeutics (GYRE) awards director 40,000 stock options vesting to 2029 - Stock Titan
Weston Claire files initial ownership report at Gyre Therapeutics (GYRE) - Stock Titan
Gyre Therapeutics director Kirkby Maxwell files initial beneficial ownership statement - Bitget
Finanzdaten der Gyre Therapeutics Inc-Aktie (GYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.11%
1.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):